PANEL OF SERUM BIOMARKERS MAY PREDICT BENEFIT FROM BEVACIZUMAB (BEV) IN ADVANCED NSCLC PATIENTS

被引：0
|
作者：
Braun, Eduardo [1 ]
Fidler, Mary Jo [1 ]
Basu, Sanjib [1 ]
Gargaram, Anjali [2 ]
Walters, Kelly [2 ]
Fhied, Cristina [2 ]
Borgia, Jeffrey A. [2 ]
Bonomi, Philip D. [1 ]
机构：
[1] Rush Univ, Med Ctr, Div Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Div Biochem, Chicago, IL 60612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [1] Panel of Serum Biomarkers May Predict Benefit from Bevacizumab (BEV) in Advanced NSCLC Patients
    Braun, E.
    Fidler, M.
    Basu, S.
    Gangaram, A.
    Walters, K. Kaiser
    Karmali, R.
    Fhied, C.
    Borgia, J. A.
    Bonomi, P. D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S219 - S219
  • [2] Panel of serum biomarkers to predict benefit from bevacizumab (BEV) in advanced NSCLC patients.
    Braun, Eduardo
    Fidler, Mary J.
    Basu, Sanjib
    Gangaram, Anjali
    Walters, Kelly Kaiser
    Karmali, Reem
    Fhied, Cristina
    Lie, Wen-rong
    Borgia, Jeffrey Allen
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09)
    Rothschild, Sacha
    Gautschi, Oliver
    Schuster, Nathalie
    Li, Qiyu
    Savic, Spasenija
    Schneider, Martina
    Biaggi, Christine
    Bubendorf, Lukas
    Brutsche, Martin
    Zippelius, Alfred
    Zander, Thilo
    Betticher, Daniel
    Fruh, Martin
    Stahel, Rolf
    Cathomas, Richard
    Rauch, Daniel
    Pless, Miklos
    Ochsenbein, Adrian
    Jaggi, Rolf
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1471 - S1471
  • [4] CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients
    Zhou, Chao
    Hou, Liqiao
    Tang, Xingni
    Liu, Changxing
    Meng, Yinnan
    Jia, Haijian
    Yang, Haihua
    Zhou, Suna
    RADIOTHERAPY AND ONCOLOGY, 2023, 183
  • [5] VEGFRS PREDICT BEVACIZUMAB BENEFIT IN ADVANCED NON SMALL CELL LUNG CANCER PATIENTS
    Zhang, Kai
    Cao, Rubo
    Fei, Shi H.
    Liu, Li
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1213 - S1213
  • [6] Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis
    Yap, Desmond Y. H.
    Seto, Wai Kay
    Fung, James
    Chok, Siu Ho
    Chan, See Ching
    Chan, Gary C. W.
    Yuen, Man Fung
    Chan, Tak Mao
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (02) : 202 - 206
  • [7] A panel of biomarkers may successfully predict acute stroke diagnosis
    Montaner, J
    Ribo, M
    Delgado, P
    Purroy, F
    Quintana, M
    Penalba, A
    Rosell, A
    Chacon, P
    Arenillas, JF
    Molina, CA
    Alvarez-Sabin, J
    STROKE, 2005, 36 (02) : 419 - 419
  • [8] Bevacizumab Combined with Chemotherapy in the Treatment of Advanced NSCLC Patients
    Tao, Hong
    Liu, Zhe
    Tang, Junfang
    Li, Mingzhi
    Shi, Liang
    Wu, Wei
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S424 - S424
  • [9] PATIENTS WITH ADVANCED IPMC MAY BENEFIT FROM NEOADJUVANT CHEMOTHERAPY
    Standring, Oliver
    Lad, Neha
    Sanchez, Susana Benitez
    Demyan, Lyudmyla
    Deutsch, Gary
    Weiss, Matthew
    Deperalta, Danielle K.
    GASTROENTEROLOGY, 2022, 162 (07) : S1360 - S1360
  • [10] Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
    Egerer, Mara
    Schuch, Kathrin
    Schoeler, David
    Artusa, Fabian
    Puengel, Tobias
    Holtman, Theresa Maria
    Loosen, Sven H.
    Demir, Muenevver
    Wree, Alexander
    Luedde, Tom
    Tacke, Frank
    Roderburg, Christoph
    Mohr, Raphael
    CANCERS, 2024, 16 (21)
12345